Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 7, 2014Innovative handle design enables physician preferences for precision, comfort and control when acquiring tissue samples during diagnostic procedures
Boston Scientific Corporation (NYSE: BSX) has received clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe for the Expect™ Slimline (SL) Needle, which is...
-
Apr 1, 2014These and Other Studies Reinforce Global Commitment to the Development of Innovative Therapies to Improve Care for Patients with Cardiovascular Disease
Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation...
-
Apr 1, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2014 on...
-
Apr 1, 2014Interim results of the EFFORTLESS registry published in the European Heart Journal
Real-world data on the Boston Scientific Corporation (NYSE:BSX) S-ICD System (Subcutaneous Implantable Defibrillator) are highlighted online this week...
-
Mar 30, 2014MADIT-CRT Long-Term Follow-up Results Presented at the American College of Cardiology and Published in the New England Journal of Medicine
In the longest follow-up to date of cardiac resynchronization therapy (CRT) for mild heart failure patients, Boston Scientific Corporation's (NYSE:...
-
Mar 27, 2014Includes Late Breaking Clinical Trial Assessing Use of the Boston Scientific CRT-D Therapyin Patients with Mild Heart Failure
At the 63rd Annual Scientific Session of the American College of Cardiology (ACC), March 29 – 31 in Washington, D.C., Boston Scientific Corporation...
-
Mar 19, 2014
Boston Scientific has received a Shingo award from the Shingo Institute, part of the Jon M. Huntsman School of Business at Utah State University, in...
-
Mar 14, 2014First implant took place in France, at the Nouvelles Cliniques Nantaises in Nantes
Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval and European market launch of the INGEVITY™ family of magnetic resonance...
Mar 12, 2014Newest Bare Metal Stent Technology Features Advanced Architecture and Provides Physicians with Enhanced Treatment Option for PatientsContinuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the REBEL™ Platinum...
-
Mar 3, 2014
The Board of Directors of Boston Scientific Corporation (NYSE: BSX) has elected Edward J. Ludwig as a Director. The appointment of Mr. Ludwig will...